Abstract. The article discusses the relationship between diseases of the pleura (pleural effusion, pleurisy, empyema) and endocrine disorders, in particular hypothyroidism, as a potential modifying factor in the course of pleural pathology. An analysis of modern literature sources on the pathogenetic mechanisms of pleural effusion
formation in thyroid dysfunction, clinical features, diagnostic approaches and effectiveness of levothyroxine replacement therapy has been carried out. It has been found that some patients with hypothyroidism develop pleural effusions, which regress after reaching euthyroid. The paper describes epidemiological, diagnostic, clinical,
pharmacological and organizational gaps in the study of this comorbid condition. The authors proposed an algorithm for the initial diagnosis of pleural effusions and routing of patients, taking into account the determination of thyroid status. ABC/VED analysis of drugs used in the pharmacotherapy of hypothyroid-associated
diseases of the pleura was performed. Levothyroxine has been shown to be a key etiotropic agent, and timely hormonal correction reduces the need for invasive procedures and improves clinical outcomes. The importance of a
multidisciplinary approach to diagnosis and treatment, which combines pulmonological, endocrinological and clinical-pharmacological aspects, is emphasized.
Keywords: pleurisy, pleural effusion, pleural empyema, hypothyroidism, thyroid dysfunction, ABC/VED analysis, endocrine-pulmonary comorbidity.

Abstract. The study of chest injuries which profoundly impact quality of life, life expectancy, disability rates, and mortality is of significant importance. In clinical research, the authors analyzed diagnostic results from 527 patients aged 18 to 85 with closed chest trauma, consisting of 82% men and 18% women. The study confirms
that traumatic chest injuries are severe conditions that necessitate strict adherence to well-defined diagnostic and treatment guidelines. It is advisable to utilize thoracoscopy and video-assisted thoracoscopy for managing hemothoraxes with small volumes of bleeding, as these minimally invasive techniques can enhance patient outcomes and reduce recovery times. The incorporation of advanced three-dimensional (3D) printing
technologies into medical practice for chest injuries is also recommended, as it can improve surgical
planning and enable personalized treatment strategies. Moreover, 3D printing can aid in the fabrication of patient-specific implants and prosthetics, thereby enhancing the effectiveness of reconstructive surgeries. Further research is needed on pharmacotherapy when using medications in accordance with the codes of the 11th revision of
the International Classification of Diseases, to optimize therapeutic efficacy. Additionally, an indepth study of the integrated ABC/VEN-analysis of drug prescriptions in pharmacotherapeutic regimens for thoracic trauma treatment dynamics in both inpatient and outpatient healthcare facilities is recommended. This could lead to better resource
allocation, improved patient care, and the development of more effective treatment protocols.
Emphasizing interdisciplinary collaborationamong surgeons, radiologists, and pharmacologists is crucial to advance the management of chest trauma, ensuring that patients receive comprehensive and holistic care throughout their
recovery process.
Keywords: quality of life, life expectancy, fatalities, trauma, chest, thoracoscopic surgery, thoracic injuries.

Хронічний панкреатит (ХП) – це запальне захворювання, що прогресує і призводить до незворотного пошкодження підшлункової залози, спричиняючи екзокринну та ендокринну недостатність. Оптимізація фармакотерапії ХП є критичним питанням через зростання поширеності захворювання та необхідність економічно ефективних та науково обґрунтованих стратегій лікування. Використання ABC/VED-аналізу надає можливість класифікувати та пріоритезувати ліки на основі їхньої клінічної значущості та економічної доцільності.
Мета. Автори дослідження мали на меті оптимізувати фармакотерапію хронічного панкреатиту із застосуванням ABC/VED-аналізу в контексті маркетингових та фармакоекономічних досліджень.
Методи. Дослідження охоплювало комплексний огляд нормативних документів, клінічних рекомендацій та фармакоекономічних оцінок. Було проведене багатопрофільне експертне опитування за участю 50 медичних працівників, включно з гастроентерологами, хірургами, ендокринологами, лікарями загальної практики та фармацевтами. ABC-аналіз застосовували для класифікації ліків на основі їхнього внеску у вартість, тоді як VED-аналіз класифікував препарати на життєво важливі (V), необхідні Україна та бажані (D) групи. У дослідженні також оцінювали нормативно-правову базу для фармакотерапії ХП на національному та міжнародному рівнях.
Результати. Дослідження виявило невідповідності між національними та міжнародними нормативно-правовими документами щодо фармакотерапії ХП. Серед 30 проаналізованих лікарських засобів п’ять препаратів (Іміпенем + Циластатин, Меропенем, Метронідазол, Цефотаксим, Ципрофлоксацин) були віднесені до всіх чотирьох регуляторних документів. ABC- аналіз засвідчив, що 82.21% загальних витрат були виділені на препарати категорії А, 15.54% - категорії B та 2.25% - категорії C. VED-аналіз виявив, що 43% препаратів були класифіковані як життєво необхідні, тоді як 57% були необхідними, при цьому жоден препарат не вважався необов’язковим. Комбінована матриця ABC/VED показала, що препарати категорії A/V мали
найбільшу частку витрат (41.54%), що підкреслює їх пріоритетність у лікуванні ХП.
Висновки. Застосування ABC/VED-аналізу у фармакотерапії ХП дає змогу структуровано та економічно обґрунтовано підійти до вибору ліків. Дослідження виявило регуляторні розбіжності, які можуть вплинути на доступність ліків та ефективність лікування. Результати дослідження надають рекомендації на основі доказів щодо оптимізації фармакотерапії ХП, забезпечуючи відповідність як міжнародним стандартам, так і національній політиці охорони здоров’я. Подальші дослідження повинні бути зосереджені на інтеграції фармакоекономічних оцінок у клінічне ухвалення рішень та на відповідному оновленні національних протоколів лікування.
Ключові слова: хронічний панкреатит, фармакотерапія, ABC-аналіз, VED-аналіз, регулювання лікарських засобів, фармакоекономіка.

Introduction 
Tuberculosis (TB) remains one of the leading  causes of death from infectious diseases in the world. The 
situation is complicated by the increasing prevalence of multidrug-resistant forms of the pathogen Mycobacterium 
tuberculosis against the background of covid, post-covid, long-covid disorders, which requires improving 
approaches to pharmacotherapy according to the requirements of ICD-11. According to the World Health 
Organization, more than ten million new cases of tuberculosis are registered in the world annually, while 
about one million three hundred thousand patients die [15]. Standard treatment of active tuberculosis, 
recommended by the World Health Organization, involves the use of a combination of at least three or four anti
tuberculosis drugs. This approach allows you to effectively combat the bacterial load, reduce the risk of developing drug resistance, shorten the duration of therapy, and reduce the frequency of relapses of the disease [6]. 
Fixed-dose combination drugs, which contain several active pharmaceutical ingredients in one dosage form, are designed to increase patient adherence to treatment and prevent dosing errors. These drugs are particularly relevant in countries with high tuberculosis incidence rates, where non-adherence to treatment regimens is common. Numerous studies have shown that fixed-dose combination drugs provide efficacy and safety comparable to single drugs, and reduce the risk of drug resistance [7, 8]. However, the use of fixed-dose combination 
drugs has certain limitations. Among patients with human immunodeficiency virus co-infection, pharmacokinetic 
interactions between anti-tuberculosis and antiretroviral drugs are possible. This can lead to changes in the 
concentration of active substances in the blood, reduced treatment efficacy, or increased toxicity [9]. In addition, 
the use of fixed-dose combination drugs may be inappropriate in cases of individual intolerance to one of 
the components or if dosage adjustment is necessary for a particular patient. Thus, despite the advantages of fixed-dose combination anti-tuberculosis drugs, their use requires an individual approach and constant monitoring of the effectiveness and safety of therapy. The rational use of such drugs in national tuberculosis control programs is a key factor in the successful control of this global health problem [10]. Overcoming multidrug-resistant tuberculosis is a challenging task, as the bacteria that cause this infection can develop resistance to standard anti-TB drugs. However, combination antimycobacterial chemotherapy remains the mainstay of treatment. It involves the use of at least three anti-TB drugs to which the bacteria are still susceptible, and the duration of treatment is at least 6 months [11, 12]. The main principles of anti-TB chemotherapy are: 
• Combination use of anti-TB drugs: The use of several drugs simultaneously reduces the risk of the development 
of resistance of TB bacteria to one of the drugs. 
• Use of standard drug combinations: Certain combinations of anti-TB drugs are defined as standard and 
are used to treat patients with new cases of TB and relapses of the disease. 
• Monitoring by healthcare professionals: Healthcare professionals should ensure that patients take their 
medications correctly and adhere to their treatment regimen. 
• Avoid adding one anti-TB drug after treatment failure: If a patient does not respond to treatment, adding another anti-TB drug to the regimen may lead to further failure. In addition, antimicrobial therapy is administered 
under the supervision of healthcare professionals, which allows for monitoring of drug use and prevention of 
potential complications. 
Regarding the convenience of taking medications, the development of combination drugs that contain the 
active pharmaceutical ingredients necessary for pharmacotherapy can help patients to facilitate their treatment regimen, improve adherence to the therapy protocol, and ensure the quality of the drugs [12]. Overall, the fight against multidrug-resistant tuberculosis requires a comprehensive approach, active collaboration between healthcare professionals and patients, as well as continuous improvement of anti-TB strategies and the development of new drugs to treat this dangerous infection. The purpose of the study was to conduct a content 
analysis of the modern range of combined anti-tuberculosis drugs registered on the pharmaceutical market of Ukraine, considering the current requirements of domestic legislation in the field of healthcare. Particular attention is paid to the study of the clinical feasibility of using fixeddose combination drugs in the pharmacotherapy of 
tuberculosis in accordance with the provisions of the sixteenth edition of the State Formulary of Medicines, 
approved by the Order of the Ministry of Health of Ukraine dated March 12, 2024 No. 418 “On Approval and 
Implementation of the Sixteenth Edition of the State Formulary of Medicines”. The work also analyzed current 
scientific sources on the effectiveness, safety, and impact of combined anti-tuberculosis pharmacotherapy on 
reducing the level of chemoresistance and increasing patient adherence to treatment.   
Materials and methods The study is of a content analysis nature and is based on a comprehensive study of open information sources related to combined anti-tuberculosis drugs. The main information resources were: scientific publications from professional domestic and international medical and pharmaceutical journals, official documents of the World Health Organization, analytical materials of international initiatives to combat tuberculosis, as well as current regulatory legal acts of Ukraine in the field of health care. The analysis of the range of combined anti
tuberculosis drugs registered in Ukraine was carried out using data from the State Register of Medicines of Ukraine. Particular attention was paid to drugs included in the sixteenth edition of the State Formulary of Medicines, approved by the Order of the Ministry of Health of Ukraine dated March 12, 2024 No. 418 “On Approval and Implementation of the Sixteenth Edition of the State Formulary of Medicines”. International non-proprietary names of active pharmaceutical ingredients, trade names of medicines, release forms, dosages, as well as their availability in state reimbursement programs were studied. In the process of research, methods of content 
analysis of scientific literature, comparative analysis of regulatory sources, classification method, as well as 
elements of a statistical approach for quantitative assessment of the presence of combined drugs on the 
pharmaceutical market of Ukraine, previous studies of foreign and domestic scientists in the direction of content 
analysis, quality of drugs [13-20] were applied. Special attention was paid to comparing data on the advantages and disadvantages of combination therapy in the context of international and national clinical guidelines, [21-23]. 
The research of the article is a fragment of research works of Private Scientific Institution "Scientific 
and Research University of Medical and Pharmaceutical Law" and Danylo Halytsky Lviv National Medical 
University on the topic "Diagnosis, treatment, pharmacotherapy of inflammatory, traumatic and onco
thoracic pathology using instrumental methods" (state registration number 0125U000071, implementation period 
2025-2031); Lviv Medical Institute on the topic of "Improving the system of circulation of drugs during 
pharmacotherapy on the basis of evidentiary and forensic pharmacy, organization, technology, biopharmacy and 
pharmaceutical law" (state registration 0120U105348, implementation period 2021-2026); Private Scientific Institution "Scientific and Research University of Medical and Pharmaceutical Law" on the topic “Multidisciplinary research of post-traumatic stress disorders during war among patients (primarily combatants)” (state registration number 0124U002540, implementation period 2024-2028). 

Abstract. For the first time in Ukraine, our team successfully  applied  extracorporeal  blood hyperthermia (EBH) within a closed-loop circuit to manage inflammatory conditions of the lungs and pleura. Controlled warming of autologous blood to 38°C and its subsequent reinfusion produced rapid, clinically  significant  reductions  in  exudative pleurisy,  pleural  empyema,  and  paracancerous inflammatory  lesions.  Earlier,  EBH  had  been 
incorporated  into  U.S.  military  field  protocols between  2003  and  2007,  and  it  is  now  formally 
included  in  therapeutic  guidelines  across  the United  States,  Canada,  New  Zealand,  multiple European nations, and several African healthcare systems.  Our  findings  corroborate  international data  showing  that  mild  systemic  hyperthermia enhances  phagocytic  activity,  improves microcirculation  within  the  pleural  cavity,  and accelerates  resorption  of  inflammatory  exudate while  maintaining  a  favorable  safety  profile.  No severe adverse events or hemodynamic instabilities were observed during or after the procedures in our 
cohort.  Beyond  its  direct  anti-inflammatory impact, EBH may potentiate antibiotic penetration into pleural tissues, offering a valuable adjunct in the  era  of  rising  antimicrobial  resistance.  Future multicenter  trials  with  larger  patient  populations and  comparative  cost-effectiveness  analyses  are warranted  to  refine  treatment  parameters  and confirm  long-term  benefits  of  this  promising modality. 
Keywords:  inflammatory  pulmonary  pathology, treatment, extracorporeal blood hyperthermia